WallStreetZenWallStreetZen

NASDAQ: MBRX
Moleculin Biotech Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for MBRX

Based on 2 analysts offering 12 month price targets for Moleculin Biotech Inc

Min Forecast
$4.00+1,365.2%
Avg Forecast
$4.00+1,365.2%
Max Forecast
$4.00+1,365.2%

Should I buy or sell MBRX stock?

Based on 2 analysts offering ratings for Moleculin Biotech Inc.

Buy
Strong Buy
0 analysts 0%
Buy
2 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their MBRX stock forecasts and price targets.

MBRX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-09-10
lockedlocked$00.00+00.00%2025-06-18

1 of 1

Forecast return on equity

Is MBRX forecast to generate an efficient return?

Insufficient data to display

Forecast return on assets

Is MBRX forecast to generate an efficient return on assets?

Company
-1,076.69%
Industry
93.69%
MBRX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

MBRX earnings per share forecast

What is MBRX's earnings per share in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
-$0.87
Avg 2 year Forecast
-$0.70
Avg 3 year Forecast
-$0.51

MBRX revenue forecast

What is MBRX's revenue in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

MBRX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
MBRX$0.27$4.00+1,365.20%Buy
CURX$0.49N/AN/A
FBLG$0.27$10.00+3,549.64%Strong Buy
LGVN$0.66$3.00+351.81%Strong Buy
TPST$3.20N/AN/A
View Top Biotech Stocks

Moleculin Biotech Stock Forecast FAQ

Is Moleculin Biotech Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: MBRX) stock is to Buy MBRX stock.

Out of 2 analysts, 0 (0%) are recommending MBRX as a Strong Buy, 2 (100%) are recommending MBRX as a Buy, 0 (0%) are recommending MBRX as a Hold, 0 (0%) are recommending MBRX as a Sell, and 0 (0%) are recommending MBRX as a Strong Sell.

If you're new to stock investing, here's how to buy Moleculin Biotech stock.

What is MBRX's earnings growth forecast for 2025-2027?

(NASDAQ: MBRX) Moleculin Biotech's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 45.68%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.81%.

Moleculin Biotech's earnings in 2025 is -$41,357,000.On average, 5 Wall Street analysts forecast MBRX's earnings for 2025 to be -$44,139,383, with the lowest MBRX earnings forecast at -$42,408,427, and the highest MBRX earnings forecast at -$45,437,600. On average, 5 Wall Street analysts forecast MBRX's earnings for 2026 to be -$35,571,150, with the lowest MBRX earnings forecast at -$42,408,427, and the highest MBRX earnings forecast at -$27,797,120.

In 2027, MBRX is forecast to generate -$25,964,343 in earnings, with the lowest earnings forecast at -$24,946,133 and the highest earnings forecast at -$26,728,000.

What is MBRX's revenue growth forecast for 2025-2027?

(NASDAQ: MBRX) Moleculin Biotech's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.11%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.31%.

Moleculin Biotech's revenue in 2025 is $0.On average, 5 Wall Street analysts forecast MBRX's revenue for 2025 to be $0, with the lowest MBRX revenue forecast at $0, and the highest MBRX revenue forecast at $0. On average, 5 Wall Street analysts forecast MBRX's revenue for 2026 to be $0, with the lowest MBRX revenue forecast at $0, and the highest MBRX revenue forecast at $0.

In 2027, MBRX is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is MBRX's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: MBRX) forecast ROA is -1,076.69%, which is lower than the forecast US Biotechnology industry average of 93.69%.

What is MBRX's Price Target?

According to 2 Wall Street analysts that have issued a 1 year MBRX price target, the average MBRX price target is $4.00, with the highest MBRX stock price forecast at $4.00 and the lowest MBRX stock price forecast at $4.00.

On average, Wall Street analysts predict that Moleculin Biotech's share price could reach $4.00 by Sep 10, 2026. The average Moleculin Biotech stock price prediction forecasts a potential upside of 1,365.2% from the current MBRX share price of $0.27.

What is MBRX's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: MBRX) Moleculin Biotech's current Earnings Per Share (EPS) is -$1.35. On average, analysts forecast that MBRX's EPS will be -$0.87 for 2025, with the lowest EPS forecast at -$0.83, and the highest EPS forecast at -$0.89. On average, analysts forecast that MBRX's EPS will be -$0.70 for 2026, with the lowest EPS forecast at -$0.83, and the highest EPS forecast at -$0.55. In 2027, MBRX's EPS is forecast to hit -$0.51 (min: -$0.49, max: -$0.53).

What is MBRX's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: MBRX) forecast ROE is N/A, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.